{"nctId":"NCT00700102","briefTitle":"A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.","startDateStruct":{"date":"2006-02"},"conditions":["Colorectal Cancer"],"count":820,"armGroups":[{"label":"Chemotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Chemotherapy"]},{"label":"Chemotherapy + Bevacizumab","type":"EXPERIMENTAL","interventionNames":["Drug: Chemotherapy","Drug: Bevacizumab"]}],"interventions":[{"name":"Chemotherapy","otherNames":[]},{"name":"Bevacizumab","otherNames":["Avastin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult patients, \\>=18 years of age\n* Metastatic colorectal cancer and disease progression\n* Previously treated with first-line chemotherapy plus Avastin\n* Eastern Cooperative Oncology Group (ECOG) performance status \\<=2.\n\nExclusion Criteria:\n\n* Diagnosis of progression of disease more than 3 months after last Avastin administration\n* First-line patients with progression-free survival in first-line of \\<3 months\n* Patients receiving less than 3 consecutive months of Avastin in first-line therapy\n* Past or current history (within the last 2 years prior to treatment start) of other malignancies, except for curatively treated basal and squamous cell cancer of the skin or in situ cancer of the cervix\n* Clinically significant cardiovascular disease within 6 months prior to start of study treatment\n* Known central nervous system (CNS) disease, except for treated CNS metastases as defined by protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival: Time From Randomization to Death From Any Cause","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"11.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival: Months From Time of First Line Therapy","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":null},{"groupId":"OG001","value":"23.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Progression Free Survival Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"394","spread":null},{"groupId":"OG001","value":"386","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival: Time to Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate: Percentage of Participants With Best Overall Response, Defined as Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST Criteria","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate: Participants With Response Status Based on RECIST Criteria","description":"Response Evaluation Criteria In Solid Tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve (\"respond\"), stay the same (\"stabilize\"), or worsen (\"progress\") during treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"5.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.2","spread":null},{"groupId":"OG001","value":"62.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null},{"groupId":"OG001","value":"21.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":null},{"groupId":"OG001","value":"10.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":137,"n":409},"commonTop":["Diarrhoea","Nausea","Vomiting","Asthenia","Neutropenia"]}}}